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Abstract Excessive generation of free radicals plays a
critical role in the pathogenesis of radiation-induced brain
injury. This study was designed to evaluate the protective
effect of edaravone, a free radical scavenger, on radiation-
induced brain necrosis in patients with nasopharyngeal car-
cinoma. Eligible patients were randomized 1:1 to the control
group and the edaravone group (intravenous 30 mg twice per
day for 2 weeks). Both groups received intravenous con-
ventional steroid therapy and were monitored by brain MRI
and LENT/SOMA scales prior to the entry of the trial and at
3-months after completing the trial. The primary end point
was a 3-month response rate of the proportional changes
determined by MRI. The trial is registered at Clinicaltri-
als.gov Identifier: NCT01865201. Between 2009 and 2012,
we enrolled 154 patients. Of whom 137 were eligible for
analysis. The volumes of necrosis estimated on T2-weighted
image showed that 55.6 % edaravone-treated patients (40
out of 72) showed edema decreases C25 %, which was
significantly higher than that in the control group (35.4 %, 23
out of 65, p = 0.025). Forty-four patients treated with eda-
ravone (61.1 %) reported improvement in neurologic
symptoms and signs evaluated by LENT/SOMA scales,
while the rate was 38.5 % in the control group (p = 0.006).
MRI of the edaravone group showed a significant decrease in
area of T1-weighted contrast enhancement (1.67 ±
4.69 cm2, p = 0.004) and the T2-weighted edema
(5.08 ± 10.32 cm2, p = 0.000). Moreover, compared with
those in control group, patients with edaravone exhibited
significantly better radiological improvement measured by
T2-weighted image (p = 0.042). Administration of edarav-
one, in adjunct to steroid regimen, might provide a better
outcome in patients with radiation-induced brain necrosis.
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Introduction
Radiation-induced brain necrosis (RN) is a serious com-
plication caused by radiation therapy. Occurrence of RN
can be acute, sub-acute, and delayed, which adversely
worsens neurologic functions and impairs the quality of life
of recipients. Corticosteroids are commonly used as a
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protective agent for RN. However they have significant
side effects depending on the dose and duration of expo-
sure. Side effects can include diabetes, iatrogenic Cushing
syndrome, myopathy, avascular necrosis, psycho-mood
disturbance, etc. [1]. Although corticosteroids may ame-
liorate the severity of the signs and symptoms related to
RN, the effect may lost once the steroids are discontinued
[2]. Alternative therapies such as hyperbaric oxygen ther-
apy, antiplatelet agents, anticoagulants, and/or vitamins
have clinically been tested but the outcomes are disap-
pointing. Antiangiogenic agent, bevacizumab has recently
been reported to be promising [3, 4], yet with flaw of
potential toxicity and high cost. Surgical debulk is one of
the treatment options but many RN lesions are inoperable
because of the location, or the fact that patients may be
medically illegible for surgery [5–7].
The pathogenesis of RN is under exploration but not
fully understood. It has been confirmed that chronic oxi-
dative stress and inflammatory reaction play key roles in
the pathogenesis of radiation-induced late normal tissue
injury [8, 9]. Free radicals can be generated directly or
indirectly by ionizing radiation [10, 11]. Ample evidence
from laboratory experiments revealed that excessive gen-
eration of free radicals causes tissue damage in many ways
by which they react on protein, lipid, and double DNA
strands resulting in metabolic disturbances and cellular
death. Specifically, the central nervous system (CNS) is
vulnerable to oxidative stress, therefore, eliminating the
insulting effects induced by free radicals, may be beneficial
in alleviation of cellular damage.
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), as
an effective free radical scavenger [12–15], has been used
in treating a wide range of oxidative stress-related diseases,
including cerebral ischemia, by scavenging free radicals
and suppressing the inflammatory reactions [16]. However,
whether edaravone has a therapeutic effect on RN is
unknown. To test this hypothesis, we carried out a pro-
spective randomized open-labeled clinical study on the
effect of edaravone on RN.
Methods
This prospective study was a 3-month, open-labeled clin-
ical trial on RN comparing the patients treated with eda-
ravone plus corticosteroid to control group treated with
corticosteroid alone. The study was performed at the
Department of Neurology of Sun Yat-Sen Memorial hos-
pital, Sun Yat-Sen University, and was approved by the
authorized human research review board in our institutes in
accordance with the Helsinki declaration. Written informed
consents were obtained from all participants.
Participants
Patients were enrolled between March 2009 and September
2012. The inclusion criteria were as follows: Have
received radiotherapy for histologically confirmed naso-
pharyngeal carcinoma; `Radiotherapy was finished
C6 months prior to study entry; ´Radiographic evidence
to support the diagnosis of RN without tumor recurrence
[17]; ˆAge C 18 years; ˜No evidence of increased
intracranial pressure suggestive of a brain herniation;
ÞRoutine laboratory studies with bilirubin B2*upper
limits of normal (ULN), aspartate aminotransferase (AST
or SGOT)\2* ULN, creatinine\1.5*ULN, red-cell count
C4,000 per cubic millimeter; white-cell count C1500 per
cubic millimeter, platelets C75,000 per cubic millimeter;
Hb C 90 g/L, prothrombin time(PT), activated partial
thromboplastin time(APTT), international normalized
ratio(INR) in a normal range; þBeing able to understand
and willing to sign a written informed consent document.
Considering the potential side effects of edaravone on liver
function, after the trial was started, we decided to enroll
patients with normal AST. The exclusion criteria were as
follows: Evidence of tumor recurrence or metastases;
`Other CNS disorders, such as cerebral vascular events,
inflammatory and neurodegenerative diseases; ´Concom-
itant significant systemic diseases such as cardiovascular
diseases; ˆHistory of anaphylactic response to edaravone.
All participants have received radical radiotherapy using a
conventional two-dimensional radiotherapy technique.
Interventions
Participants were randomized in the ratio of 1:1 into the
control group and the edaravone group. All participants
received a conventional corticosteroid regimen (adminis-
tration of daily intravenous methylprednisolone 500 mg
for 3 consecutive days followed by oral prednisolone
tapering down to off in 30 days. Edaravone was given at
30 mg, twice per day for 14 days as a reference of the
dosage used in patients with ischemic stroke [18].
Demographic data, total dose (Gy), diagnosis, treatments,
clinical and radiographic responses of participants were
collected.
Outcomes
Clinical symptoms and signs were evaluated by Late
Effects of Normal Tissues –Subjective, Objective, Man-
agement, Analytic (LENT/SOMA) scale [19] before entry
of the trial and 3 months after treatment. Subjective
domain contains five items: headache, somnolence, intel-
lectual deficit, functional competence, and memory.
Objective domain contains four items: neurologic deficit,
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cognitive functions, mood & personality changes, and
seizures. Analytic domain includes neuropsychologic and
radiological assessments. Each parameter scores from 1 to
4, score 0 if there are no toxicities. The total of each
parameter represents the final score of the LENT/SOMA
scale [19]. The radiological response was assessed by MRI
difference between pretreatment and post-treatment, which
included T1-weighted gadolinium contrast-enhanced and
T2-weighted image. The edge of the maximum area of each
lesion was draw by the manual approach and calculated
automatically by software Volume Viewer 2(GE, AW
Suite 2.0, 6.5.1.z). MRI studies were evaluated by two
neuroradiologists who were blinded to the grouping.
The primary endpoint was the proportion of the edema
reduction in area at 3 months. A reduction in edema area of
C25 % constituted a response, which was estimated on T2-
weighted images. The LENT/SOMA scale score was
selected as the secondary endpoint measures.
Statistical analysis
We designed the present study with an a of 0.05, and
power of 90 %. In order to detect an increase of 30 % in
response rate between the two arms, the estimated sample
size for this study was 112 patients (56 patients in each
arm). The data were expressed as mean ± standard devi-
ation (SD). T test was used to compare age, radiation dose,
latency of RN between the edaravone group and the control
group. LENT/SOMA scale scores between the two groups
were assessed by Mann–Whitney U Test. The v2 test was
used to analyze the therapeutic efficacy. Differences in the
T1-weighted gadolinium enhancement and T2-weighted
image between the two groups were also evaluated by




Between March 2009 and September 2012, a total of 162
patients were added to the study. Of these, 154 who ful-
filled the inclusion criteria were enrolled in the study.
Seventy-seven were enrolled in the edaravone-treated
group and another 77 in the control group. During the
study, 17 (5 in edeverone group and 12 in control group)
withdrew. In control group, one patient suffered from
severe pulmonary infection and could not continue the
corticosteroid therapy. Five patents in the control group
asked for edaravone, therefore also withdrew from the
protocol. A total of 11 patients were lost to follow-up. The
final number of the subjects in the study was 137, namely
72 in edavarone group and 65 in control group, as shown in
Fig. 1.
All participants received radiotherapy at a total dose of
68–82 Gy (2 Gy/fraction, 5 fractions per week). The
patients’ age ranged from 25 to 80 years old, with an
Fig. 1 Flow diagram of our
study
J Neurooncol (2014) 120:441–447 443
123
average of 50.6 ± 10 years. The latency from radiotherapy
to diagnosis of RN was 5.4 ± 4.2 years. The most frequent
symptoms were headache, dizziness, fatigue, dysphasia,
hearing loss, memory decline, personality change, and
seizures. Twenty-seven patients (19.7 %) had clinical evi-
dence of cranial nerve palsy. Clinical data of the two
groups are summarized in Table 1. There were no statis-
tical differences between the two groups regarding age,
gender, latency of RN, total radiation dose, scores of
LENT/SOMA scale at baseline, and maximum area of
necrosis lesions.
MRI observations
MRI scan was obtained at the baseline prior to the entry of
the trial and 3 months after completing the trial. Forty
patients in edaravone group and twenty-three patients in
control group exhibited radiological improvement (55.6 vs.
35.4 %, p = 0.025). Though both two groups showed
significantly decreased edema area measured in T2-
weighted MRI (edaravone group 5.08 ± 10.32 cm2,
p = 0.000; control group 2.05 ± 6.71 cm2, p = 0.016),
more reduced edema area was demonstrated in edaravone
group compared with that in the control group (p = 0.042).
Notably, patients in both groups showed a significant
decrease in the size of the T1-weighted gadolinium
enhancement (edaravone group, 1.67 ± 4.69 cm2,
p = 0.004; control group, 1.20 ± 2.71 cm2, p = 0.001,
Table 2), but it did not reach the statistical difference
between the two groups (p = 0.468, Table 2). Figure 2
showed a representative images obtained in a patient with
edaravone.
LENT/SOMA scale results
LENT/SOMA scale was evaluated before treatment and
3 months after treatment. A reduction in score of the
LENT/SOMA scale of C1 constituted an improvement.
Forty-four in the edaravone group and 25 control group
patients showed clinical improvement, from which a sig-
nificantly better response was observed in edaravone group
than that of the control group (61.1 vs. 38.5 %, p = 0.006,
Table 2).
Adverse events
The adverse events are listed in Table 3. Nine of 72
patients in edaravone group and 10 of 65 in the control
group had adverse events, without significant difference
between two groups. Of these 19 events, none of them were
serious: seven were insomnia, six high blood glucose, three
epistaxis, two mild dysfunction of liver and one
hypertension.
Discussion
RN is a serious complication of radiotherapy. It may cause
significant focal dysfunction and/or cognitive impairment.
The incidence of RN was reported to be 4.6 % in 10 years to
35 % in 3.5 years after radiotherapy [20]. Although corti-
costeroid is employed as the major conventional therapeutic
agent for RN, its efficacy remains unsatisfactory [21].







Age (year) 49.2 ± 9.2 52.0 ± 11.0 0.099
Gender
Male 56 52 0.835
Female 16 13
Primary tumor NPC NPC 1.000
Cranial nerve palsy 14 13 1.000
Latency of RN (year) 5.6 ± 4.6 5.1 ± 3.7 0.508
Conventional RT (Gy) 72.6 ± 3.1 71.4 ± 3.3 0.052
LENT/SOMA scores





6.77 ± 5.09 7.68 ± 4.77 0.286
T2-weithted area (cm
2) 19.42 ± 10.54 22.58 ± 10.09 0.075
NPC nasopharyngeal carcinoma, RN radiation-induced brain necrosis,
RT radiotherapy











Improved 44 (61.1) 25 (38.5) 0.006
Ineffective 28 (38.9) 40 (61.5)
MRI
Reduction in T1 ? C
(cm2)
1.67 ± 4.69 1.20 ± 2.71 0.468
Reduction in T2 (cm
2) 5.08 ± 10.32 2.05 ± 6.71 0.042
T1 ? C T1-weighted gadolinium contrast enhancement
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Previous studies have shown that the free radical scav-
enger, edaravone, bears neuroprotective effect in some
oxidative stress-related diseases [16, 22, 23]. The amenable
mechanism of edaravone in this regard is believed to
suppress the production of free radicals and scavenge
reactive oxidative species in the brain [24]. This anti-oxi-
dative property protects cellular structures from oxidative
injury and cell death because oxidative stress has been
confirmed in mediating radiation-induced injury [25]. It
may also prevent the neural precursor cells from apoptosis
in the neurogenesis zone of the brain [26, 27]. In addition,
edaravone inhibits the expression of vascular endothelium
growth factor in astrocytes [28], and has been shown to
protect neurons from cell death after irradiation [27]. These
observations suggest that edaravone may have a protective
effect on the brain from development of RN.
In our study, patients in both edaravone and control
groups exhibited a significant reduction in T1-weighted
Fig. 2 MRI of one patient in edaravone group. a, b showed left temporal lobe necrosis (arrow head) before treatment. Three months after
treatment, T2-weighted edema (c) and T1-weighted gadolinium contrast-enhancement (d) were significantly reduced
Table 3 Adverse events in the two groups
Edaravone group
(n = 72) (%)
Control group
(n = 65) (%)
p value
Epistaxis 1 (1.4) 2 (3.1) 0.604
High blood glucose 3 (4.2) 3 (4.6) 1.000
Dysfunction of liver* 2 (2.7) 0 (0.0) 0.498
Hypertension 0 (0.0) 1 (1.5) 0.474
Insomnia 3 (4.2) 4 (6.2) 0.708
* Dysfunction of liver was defined as aspartate aminotransferase or
alanine aminotranferase [/= 2 * upper limits of normal
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contrast enhancement and T2-weighted edema. Moreover,
edaravone-treated patients have a significantly reduced
edema area compared with that of patients from control
group, indicating that adding edaravone to corticosteroid
regimen can enhance radiological improvement relevant to
RN. Although no statistical significance was observed in
T1-weighted image between the two groups in our study, it
may be due to the small size of the samples. Our results
also demonstrated that clinical symptoms did not always
parallel with the MR imaging. Some patients might have
symptoms virtually gone without significant recovery of
necrosis lesions.
Several therapeutic agents adjunct to the conventional
corticosteroid regimen have been tested for RN in the past
two decades (e.g. anticoagulants, anti-platelets, hyperbaric
oxygen therapy), but their use is not widely accepted
because of the potential adverse effects and limited ran-
domized control trials. Since radiotherapy on head and
neck may cause carotid stenosis [29], intracranial hemor-
rhage or epistaxia, the therapeutic agent adjunct to corti-
costeroid must be safe from leading to ischemic or
hemorrhagic events. Edaravone has been reported to be
effective in ischemic stroke and aneurismal subarachnoid
hemorrhage [23], it may be safe in RN too. In our study,
the fact that no fatal or severe adverse events were
observed in the edaravone group supported our notion.
In conclusion, our results suggested that administration
of edaravone adjunct to the conventional corticosteroid
regimen may be beneficial in reduction of RN. To validate
the neuroprotective effect of edaravone, a large scale study
is warranted, and the long term effect of edaravone therapy
should be elucidated. In addition, the edaravone-treated
patients needed additional charges for the drug, although
they had a better clinical outcome. Thus, cost-benefit
analysis is also recommended for its further usage.
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